Soft tissue sarcoma
Drug research and approvals for soft tissue sarcoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 545 studies of soft tissue sarcoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 14 drug trials for it since 2013, FDA has 8 approved and 55 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 545
- Trials authorized in Canada: 14
- FDA orphan approvals: 8
- EU medicines: 1
- Doxorubicin Plus Dacarbazine Versus Doxorubicin Alone as First-Line Therapy for Metastatic or Recurrent Uterine…NCT07942168 · Phase 2 · Blokhin's Russian Cancer Research Center · starts Jan 24, 2023
- Shadow-Mode Evaluation of an AI Assistant for Multidisciplinary Tumor BoardsNCT07939139 · Not reported · Technical University of Munich · starts Nov 9, 2026
- A Multicenter Phase II Clinical Trial Evaluating 68Ga-HX01 Injection for PET/CT ImagingNCT07920835 · Phase 2 · Hexin (Suzhou) Pharmaceutical Technology Co., Ltd · starts Jan 1, 2026
- Zemetostat With Anlotinib in Patients With Recurrent/Metastatic Head and Neck Soft Tissue SarcomaNCT07917949 · Phase 2 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · starts Nov 10, 2026
- Retroperitoneal Tumor RegistryNCT07915895 · Not reported · The First Hospital of Jilin University · starts Dec 1, 2024
- Preliminary Clinical Study of Entinostat in Children With Malignant Soft Tissue Sarcoma Harboring PAX-family Gene…NCT07888114 · Phase 1 · Beijing Tongren Hospital · starts Mar 15, 2025
- Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic LesionsNCT07883798 · Not reported · Affidea Nu-med Center of Oncological DIagnostics and Therapy · starts Oct 6, 2026
- Treatment Patterns and Survival Outcomes in High-Grade Osteosarcoma: A Multicenter Retrospective StudyNCT07878364 · Not reported · MedPacto, Inc. · starts Jul 13, 2026
- PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult…NCT07874828 · Phase 2 · M.D. Anderson Cancer Center · starts Oct 14, 2026
| Apr 4, 2025 | A phase 1b trial of BOLD-100 plus doxorubicin in advanced soft tissue sarcomasBOLD-100 | University Health Network | Closed |
| Jul 18, 2024 | A multicenter, randomized, phase 3 study to assess the efficacy and safety of intratumorally administered INT230-6 (shao, vinblastine, cisplatin) compared with…INT230-6 (cisplatin-vinblastine) | Intensity Therapeutics | Ongoing |
| Feb 12, 2024 | Randomized phase 2 study of cabozantinib, ipilimumab, and nivolumab in patients with soft tissue sarcomaCabozantinib/ Ipilimumab/ Nivolumab | Princess Margaret Cancer Centre | Closed |
| Oct 19, 2020 | A phase 1 study of metronomic selinexor in select soft tissue sarcomas and split dosing of selinexor in all soft tissue sarcomasSelinexor (KPT-330) | Princess Margaret Cancer Centre | Closed |
| Jul 3, 2019 | A phase 2 study of talimogene laherparepvec (t-vec) and radiation in localized soft tissue sarcomaImlygic (talimogene laherparepvec [t-vec]) | Princess Margaret Phase I Consortium | Pending |
| Jun 19, 2019 | An open-label, multi-center patient access program of olaratumab for the treatment of soft tissue sarcomaOlaratumab (LY3012207) | Eli Lilly | Ongoing |
| Apr 8, 2019 | A phase 1/2 study to investigate the safety, pharmacokinetics and efficacy of EDO-S101, a first-in-class alkylating histone deacetylase inhibition (HDACI)…Tinostamustine (EDO-S101) | Mundipharma Research Limited | Closed |
| Jul 17, 2018 | "a phase II randomized controlled trial of neoadjuvant pembrolizumab with radiotherapy and adjuvant pembrolizumab in patients with high-risk, localized soft…Keytruda | McGill University Health Centre | Pending |
| Feb 16, 2018 | A prospective study of hypoxia imaging in patients with soft tissue sarcoma using positron emission tomography (PET) with 18f-fluoroazomycin arabinoside…18F-fluoroazomycin arabinoside (18F-FAZA) | Princess Margaret Hospital | Ongoing |
| Sep 9, 2015 | A randomized, double-blind, placebo-controlled, phase 3 trial of doxorubicin plus olaratumab versus doxorubicin plus placebo in patients with advanced or…LY3012207 (olaratumab) / Doxorubicin hydrochloride | Eli Lilly | Ongoing |
| Jun 17, 2026 | TecelraTreatment of adults and pediatric patients 12 years of age and older with unresectable or metastatic synovial sarcoma who have received… | Uswm CT, LLC | Approved |
| Aug 1, 2024 | TecelraTreatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P,… | Uswm CT, LLC | Approved |
| Dec 9, 2022 | TecentriqAs a single agent for the treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft… | Genentech, Inc. | Approved |
| Jan 23, 2020 | TazemetostatTAZVERIK is indicated for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced… | Epizyme, Inc. | Approved |
| Oct 19, 2016 | LartruvoIn combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an… | Eli Lilly and Company | Approved |
| Jan 28, 2016 | HalavenTreatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen | Eisai Inc. | Approved |
| Oct 23, 2015 | YondelisFor the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing… | Janssen Research & Development, LLC | Approved |
| Apr 26, 2012 | VotrientAdvanced soft tissue sarcoma (STS) who have received prior chemotherapy | Novartis Pharmaceuticals Corp | Approved |
| Oct 22, 2026 | 177Lu-FAP-VG11 radionuclide drug conjugateTreatment of soft tissue sarcoma | VitsGen Therapeutics Inc. | Designated |
| Sep 22, 2026 | Synthetic mRNA designed to destabilize 3′UTR (untranslated…Treatment of soft tissue sarcoma, including rhabdomyosarcoma | UTR Therapeutics Inc. | Designated |
| Jun 9, 2026 | Alpha-emitting radiolabeled small molecule that selectively…Treatment of soft tissue sarcoma | Ratio Therapeutics, Inc. | Designated |
| May 28, 2026 | Recombinant, single-chain, human Interleukin-12 linked to a…Treatment of soft tissue sarcoma | Guidant BioTherapeutics Inc. | Designated |
| May 18, 2026 | LegubicinTreatment of soft tissue sarcoma | Catalysis Therapeutics Inc. | Designated |
| Apr 12, 2026 | Eftilagimod alfaTreatment of soft tissue sarcoma | Immutep S.A.S | Designated |
| Mar 17, 2026 | Zika virus strain ZIKV-Nicaragua/2016Treatment of soft tissue sarcoma, including rhabdomyosarcoma | The Nemours Foundation | Designated |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Apr 25, 2025 | Trabectedin AccordTrabectedin · generic | Accord Healthcare S.L.U. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA